Participant flow

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma · Source last updated 2021-03-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin Pembrolizumab: 200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses Radiation Therapy: 70 Gy in 35 fractions over 7 weeks Cisplatin: 100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.

   id

   FG000

   title

   Pembrolizumab

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice